einstein (São Paulo). 12/Nov/2020;18:eCE5754.
Evidence that justifies reviewing policies of access to medicines for chronic obstructive pulmonary disease in the Brazilian Public Health System
DOI: 10.31744/einstein_journal/2020CE5754
Dear Editor,
Szpak et al., demonstrated an expressive increase in expenses by the State Health Authority of Paraná associated to judicialization of access to tiotropium bromide for treatment of chronic obstructive pulmonary disease (COPD), and the relevant individual financial impact provided by the drug.() Based on these findings, the authors indicated the need to revise the clinical protocol of the disease, and insert new therapeutic options on the National Formulary of Essential Medicines. However, although we agree with this observation, we understand the rationale presented by the authors lacks more consistent evidence to guide the process of adding technologies to the Brazilian Public Health System (SUS – Sistema Único de Saúde ).
[…]
335